Reports on the approval of the U.S. Food and Drug Administration for the treatment of inhalation anthrax. Increase of the number of gastrointestinal anthrax; Accounts on the risk factor for the development of cutaneous anthrax; Emphasis on the events considered as an act of bioterrorism; Use of genetic fingerprints to trace the source of anthrax.